The phenotypic defects of two type 1 Mahoney poliovirus mutants, termed VP1-101 and VP1-102, were caused by two different small deletions in the region of the RNA genome encoding the amino terminus of the capsid protein VP1. This portion of VP1 was unresolved in the three-dimensional structure of the poliovirion, buried within the virion, and likely to interact with the viral RNA. Both VP1-101 and VP1-102 showed a diminished ability to enter CV1 but not HeLa cells; both mutants formed plaques on CV1 and HeLa cells that were smaller than wild type. Neither the rate of binding to cells nor the rate of subsequent receptor-dependent conformational change of the mutant poliovirions was affected. However, both mutants displayed delayed kinetics of RNA release compared with wild-type virus. One of the mutants, VP1-102, also displayed a defect in viral morphogenesis: 75S empty capsids formed normally, but 150S particles that contained RNA accumulated much more slowly. We suggest that the VP1-102 mutation affects RNA encapsidation as well as RNA release, whereas the VP1-101 mutation affects only RNA release. Therefore, RNA packaging and RNA release are genetically linked but can be mutated separately in different VP1 alleles, and both processes involve the amino terminus of VP1.
The primary functions of viral capsids are to protect viral nucleic acids and to escort them into and out of host cells. The three-dimensional structure of the poliovirion has been determined by X-ray crystallography (17) , providing insight into the way the virus might bind to its receptor and assemble in an infected cell. However, questions about function, such as how the poliovirus capsid allows the release of the viral RNA into the cell and how the capsid proteins assemble around the viral RNA to produce infectious stable virions, cannot be answered by understanding the structure alone. These questions can also be productively addressed by genetic and biochemical analysis of mutants defective in the processes of interest. Careful genetic analysis of poliovirus and certain other positive-strand RNA viruses is now possible due to the availability of infectious cDNA copies of the viral RNA genomes (31) .
The construction and characterization of two Mahoney type 1 poliovirus mutants, VP1-101 and VP1-102, are reported in the accompanying paper (19) . The mutations responsible for the phenotypic defects of these mutants are both small, in-frame deletions in the amino terminus of VP1. The phenotypes of these mutants include a reduction in the number of plaques formed on CV1 cells relative to that on HeLa cells and a diminution of plaque size on both cell types compared with wild-type poliovirus; these phenotypes are most apparent at 39.5°C (19) . Here, I dissect the biochemical defects that are presumably responsible for the mutant phenotypes, with the goal of understanding the role of the amino-terminal sequences of VP1 in the function of the poliovirus capsid.
A poliovirus infection is initiated by the binding of the virion to the poliovirus receptor on the surface of the human or monkey cell. The human poliovirus receptor has recently been cloned, sequenced, and identified as a member of the immunoglobulin superfamily of cell surface molecules (25) . The uptake of the virus into the cell subsequent to receptor binding is thought to occur by endocytosis of the virionreceptor complex, because infection by poliovirus (22) and other picornaviruses (28) is inhibited by chloroquine and ammonium chloride, agents that prevent vesicle acidification.
During cell entry, poliovirions undergo structural transitions in complex with the cellular receptors (34) . The first such transition corresponds to a large conformational change: VP4, one of the capsid proteins, is lost; the altered particle displays a decreased sedimentation rate and increased protease sensitivity (12) ; and the viral RNA becomes sensitive to RNase A in the presence of sodium dodecyl sulfate (SDS) (16) . If such altered poliovirions are recovered from the cell that they are in the process of infecting, they are uninfectious (18) . The molecular details of this conformational change are not known, but it is a step that appears to be on the pathway to productive infection for all picomaviruses (10) . Virion alteration has been shown to occur in cell-free membrane fractions (16, 18) and is similar to the structural transition that occurs during inactivation of poliovirions with heat or alkali (10) .
Several antiviral compounds, including arildone (7, 24) , rhodanine (13) , WIN 51711 (41) , and Ro 09-0410 (29) , have been reported to block picornavirus infection by blocking viral "uncoating" or "eclipse," steps which correspond to the conformational change described above for poliovirus that results in the loss of VP4 and virion infectivity. The three-dimensional structure of human rhinovirus 14, another picornavirus, has been determined by X-ray crystallography in the presence (2, 37) and absence (33) of several such antiviral compounds. The inhibitors bind to the viral capsid and occupy a "pore" directly beneath an indentation encircling the five-fold symmetry axis of the icosahedral virion that is thought to be the binding site (9, 33) for ICAM-1, the major rhinovirus receptor (15, 38) . The antiviral compounds have been proposed to act by making the picomavirus structures more rigid, increasing viral stability and preventing the conformational changes that are required for successful entry into target cells (2, 37) .
Release of the viral RNA into the cell occurs subsequent to this conformational change. At this step, the viral RNA becomes RNase A sensitive even in the absence of SDS (16) , and virions that have matured in the presence of photoreactive dyes become light insensitive (40) . Actually, the loss of light sensitivity of dye-containing virus particles, while thought to be correlated with RNA release, could coincide either with the physical release of the RNA or with a structural transition allowing the viral particle to become freely permeable to solvent (10, 22) , an ambiguity addressed by the findings presented here.
After a poliovirus infection is initiated, new viral RNA and proteins accumulate. Although subviral particles of various sizes, as well as newly synthesized infectious virions, can be observed within the infected cell, the actual pathway of viral assembly has not been clarified. Probable scenarios describe 5S particles, which contain one copy each of VPO, VP1, and VP3, associating to form 14S particles or "pentamers," which contain five copies each of VPO, VP1, and VP3. These 14S particles may condense around the viral RNA directly or assemble first into 75S icosahedral "empty capsids" or "procapsids," containing 60 copies each of VPO, VP1, and VP3. A morphogenesis pathway that involves the 75S particles directly must then include a step in which the RNA threads into the empty capsid (34) . In any case, 75S particles are found in infected cells, can be assembled in vitro from 14S subunits (30) , and at least reflect the intrinsic selfassembling properties of the 14S particles (3). A particle whose reported sedimentation rate has ranged from 125S to 150S, termed the provirion, is thought to contain one copy of the 7,500-nucleotide viral RNA and 60 copies each of VPO, VP1, and VP3. Autoproteolytic cleavage of VPO to the final products VP2 and VP4 would then be required to convert provirions into infectious 150S virions (1, 17, 33, 34) .
The completed poliovirions consist of 60 copies each of VP1, VP2, VP3, and VP4 and one copy of the 7,500-nucleotide viral RNA and are resistant to a variety of treatments, including SDS, RNase, and low pH. Only a small percentage of the SDS-resistant 150S particles isolated from infected cells are infectious, however; the particle/PFU ratio for poliovirus can be in the thousands (10, 23, 34) . Due to the large proportion of uninfectious virions present in any virion preparation, interpretation of the results of any biochemical experiments performed on a virion population is subject to the assumption that the biochemical properties of the infectious subpopulation are accurately represented. For this reason, I have chosen to analyze the VP1 mutant defects primarily by assays that measure only the infectious population.
As discussed in the accompanying paper (19) , the deletion responsible for the phenotype of VP1-101 removes amino acids 8 and 9 from VP1, and the deletion of amino acids 1 to 4 from VP1 causes the VP1-102 phenotype. Even though the glutamine-glycine cleavage site for the viral 3C protease is altered in VP2-102, proteolytic processing appears to be normal (19) . The drawing in Fig. 1 shows the amino acid backbone of VP1 and its orientation with respect to one of the five-fold symmetry axes of the icosahedral virion. The arrow denotes the amino terminus of VP1 as it projects into the interior of the particle (17) . Analysis of the defects in these two mutants may delineate the wild-type functions of these sequences. It is shown here that both RNA packaging and RNA release can be affected by mutation of the amino terminus of VP1.
MATERIALS AND METHODS
Cells and viruses. Cell lines and growth conditions were as described in the accompanying report (19 The monolayers were then washed twice with phosphatebuffered saline (PBS); 10 ml of Dulbecco modified Eagle medium (DME) supplemented with 10% fetal calf serum (GIBCO) was added to each plate, and incubation was continued for 90 min. Subsequently, the medium was removed and the cells were dislodged from the petri dishes with 1 ml of a 0.4% trypsin solution (Irvine Scientific). Ten milliliters of DME supplemented with 10% calf serum (GIBCO) was added to the trypsin mixture. The cells were sedimented by centrifugation at 800 x g for 5 min and resuspended in 5 ml of DME with 10% calf serum. Four sequential 10-fold dilutions of the cells were made in DME with 10% calf serum, and 0.5 ml of each dilution was added directly to HeLa and CV1 cell monolayers in 100-ml petri dishes. Agar overlays containing 0.9% Bacto-agar (Difco Laboratories), DME, and 10% calf serum were added immediately. Wild-type, VP1-101, and VP1-102 plates were incubated at 39.5°C for 44 h; 3NC-202 plates were incubated at 32.5°C for 72 h. After removal of the agar overlay, plates were stained with crystal violet as described before (6) .
DNA plasmids and RNA transfections. Plasmid pT7D (35) , in which the full-length poliovirus cDNA is located downstream of a T7 RNA polymerase promoter, was kindly provided by P. Sarnow ( (20, 32) , in T7-polio with the corresponding fragment from pVP1-101 and pVP1-102, respectively. Digestion of the plasmids with MluI, T7 transcription, and DEAE transfection were all performed as described by Sarnow (35 39 .5°C for various time periods. After incubation, an additional 0.5 ml of PBS was added to each plate, the cells were harvested by scraping, and cytoplasmic extracts were prepared and titered by plaque assay on HeLa cells.
Neutral red-containing virus was prepared for the RNA release assays by harvesting wild-type, VP1-101, and VP1-102 virus from HeLa monolayers grown in the presence of 10 jig of neutral red (Aldrich) per ml as described before (11, 40 Fig. 3 , the smallplaque phenotypes of both VP1-101 and VP1-102 were still evident in the infectious-center assays.
Apparently, an early, MOI-dependent defect is responsible for the plaque reduction of both VP1-101 and VP1-102 virions on CV1 cells. This conclusion is also consistent with the MOI dependence of the RNA synthesis data (Fig. 2) Table 2 . Again, neither the percentages of wild-type, VP1-101, or PFU that bound to the cells nor the HeLa/CV1 ratios of those percentages differed significantly. The percentages of bound PFU were lower than the percentages of bound labeled particles for each virus. This probably resulted from the conformational alteration of those particles subsequent to binding (see next section). It is shown below, however, that conformational alteration of the mutant and wild-type virions proceeds at identical rates, so any differential effect of alteration on these results is excluded. Thus, the physical binding of VP1-101 and VP1-102 to HeLa and CV1 cells is unaffected by the mutations. Similar ratios of binding to CV1 and HeLa cells of infectious mutant and wild-type particles were also seen at 4°C (Table 2) , at which temperature conformational alterations subsequent to binding do not occur.
Neither the rate nor the extent of viral alteration is changed in VP1-101 or VP1-102. Subsequent to binding to the viral receptor at the cell surface, conformational changes in the poliovirion ensue that have been termed alteration. Empirically, alteration has been correlated with numerous physical changes in virion structure, such as loss of VP4, increased RNase and protease sensitivity, and decreased sedimentation rate (10, 34) . Here, loss of infectivity was used as an assay of alteration in order to measure only the infectious population of virions. Conformational change leading to loss of infectivity does not occur at lower temperatures (10) . Populations of infecting viruses can therefore be synchronized by prebinding at 40C. A temperature switch to 39.50C then allows the bound virions to begin their postbinding processes simultaneously.
The results of such experiments are shown in Fig. 4 . After prebinding at 40C for 60 min, viruses bound to cells were recovered after various periods of incubation at 39.50C. The titers of the resulting virus stocks were determined by plaque assay. The amount of infectious virus present after prebinding at 40C, with no incubation at 39.50C, was defined as 100% unaltered. Soon after incubation at 39.5°C began, the bound virions lost infectivity; more than half were altered after 15 min. The time courses in Fig. 4 display both the rates and extents of uncoating of wild type, VP1-101, and VP1-102 on CV1 and HeLa cells. No significant mutant-specific differences were seen on either cell line. Alteration of the viral particles seemed to proceed normally for both VP1-101 and VP1-102, and any defect in cell entry must occur later.
VP1-101 and VP1-102 display altered rates of RNA release on both CV1 and HeLa cells. RNA release, the step at which the viral RNA is released from the viral capsid, has been defined as the point at which the viral RNA becomes RNase sensitive in the absence of ionic detergent (16) . In an attempt to measure the infectious population of viral particles directly, the loss of photosensitivity of virions grown in the presence of a chromogenic dye (11, 40) was monitored. For this assay, virus stocks were prepared in the presence of neutral red; the resulting NR virus was able to initiate an infection normally so long as it was kept in the dark. The period of light sensitivity has been correlated with the time required for the virus to release its RNA (10, 40) . It is thought that, after RNA release, the reversibly bound dye molecules can diffuse away from the RNA with which they were encapsidated, and thus the RNA can no longer be destroyed by irradiation (10).
In Fig. 5 , the results of experiments in which the escape of the viral RNA from copackaging with the neutral red dye molecules was monitored are shown. Wild-type, VP1-101, and VP1-102 viruses were prebound to monolayers of CV1 and HeLa cells at 4°C; the monolayers were then washed extensively and transferred to 39.5°C incubators for various periods of time. All manipulations were performed under low levels of red light as described before (40) . Figure 5a shows the results of one such experiment. The first plates on the left show the results of infecting HeLa cells with NRwild-type and NR-VP1-101 viruses with no irradiation; approximately 200 plaques formed on each plate. The second set of plates shows the result of irradiating the cells (Materials and Methods) before any incubation at 39.5°C; more than 95% of the infectious virus was inactivated. With increasing periods of incubation time at 39.5°C, increasing amounts of virus escaped inactivation; by 60 min, 100% of the wild-type virus was immune to irradiation. The amount of NR-VP1-101 virus, however, increased more slowly; the difference was seen most clearly at the 10-and 20-min time points. Furthermore, the total extent of escape of NR-VP1-101 viruses from irradiation sensitivity at the last time point was also lower than that of the wild-type virus.
These data are shown graphically in Fig. Sb and c . In both graphs, the number of plaques that formed with no irradiation at all is defined as 100%, and all other values are given as a percentage of this unirradiated-control value. On CV1 cells (Fig. 5b) , a pronounced lag in the loss of sensitivity to irradiation was observed for both mutants, indicating that both VP1-101 and VP1-102 show a defect in RNA release under these conditions. The times at which 50% of the viruses had released their RNA, t112, for wild type, (34) . In this experiment, the extent of RNA encapsidation in a given infection was estimated from the amount of material in the 150S peak, and the relative amount of RNA-less subviral particles present in the infection was estimated from the amount of material in the 75S peak.
The tracings in Fig. 6a show the viral and subviral particle profiles from CV1 cells infected with wild-type, VP1-101, and VP1-102 viruses at high MOIs to overcome the cell entry defects of the mutants. ing occurred more slowly. Surprisingly, a larger amount of 150S material accumulated relative to the 75S peak in the VP1-101 infection; this effect was only somewhat reproducible, but may represent a slightly increased rate of RNA packaging in VP1-101. The same experiment is shown in Fig. 6b , but the labeling with [35S]methionine was continued for 90 min. Again, the 150S peak was greatly reduced in the VP1-102 infection relative to either the wild-type or VP1-101 infections of CV1 cells. VP1-102 virion or provirion particles were formed, but apparently at a greatly diminished rate.
The viral and subviral particles made during a 90-min labeling of HeLa cells are shown in Fig. 6c . The relative abundance of the 150S peak was again lower for the VP1-102 infection, although the effect was less dramatic than on CV1 cells. Therefore, the rate of RNA packaging in VP1-102 infections appears to be diminished in both CV1 and HeLa cells; this effect may be responsible for the extremely small size of the VP1-102 plaques on both cell lines (Fig. 3) (26) .
The results of a complementation experiment are presented in Table 3 . To be able to detect the mutant plaques for subsequent analysis, the coinfecting virus used was 3NC-202, a temperature-sensitive mutant whose defect is in RNA replication and whose capsid proteins are wild type in sequence and function (36) . Because 3NC-202 does not replicate at 39.5°C, a high MOI was used to ensure that some nonmutant viral proteins were made from the infecting 3NC-202 RNA.
In infection 1 ( Deletion of amino acids 8 and 9, the lesion sustained by mutant VP1-101, had no effect on the binding of the virus to cells or the subsequent conformational alteration of the virion that renders it uninfectious. When time courses of the loss of photoinactivation of wild-type and VP1-101 viruses grown in the presence of neutral red were compared, however, a pronounced delay was observed for VP1-101 (Fig. 5) .
The loss of photoinactivation of viruses in which chromogenic dyes are copackaged with the viral RNA presumably measures a structural change that allows the diffusion of dye molecules away from the viral RNA. It has not been clear, however, whether this transition corresponds to physical RNA release or only to conformational alteration of the virion (10, 22) . The differences between the time course of the conformational change resulting in loss of infectivity (Fig. 4) and the kinetics of loss of light sensitivity of NR virus (Fig. 5) reported here may help to resolve this uncertainty. The two assays clearly measured different structural transitions, with the transition corresponding to loss of photosensitivity occurring subsequent to the transition corresponding to loss of infectivity. Receptor-dependent loss of viral infectivity has been well correlated with a variety of structural alterations in the virion (10, 22, 34) . It seems reasonable to conclude that loss of photosensitivity of NR virus corresponds to the physical uncoating of the viral RNA occurring after the first structural alteration.
Thus, VP1-101 virus displayed delayed RNA release from the mutant viral capsid. The VP1-101 mutation also caused the plaque and growth rate phenotypes of the VP1-101 mutant: fewer and smaller plaques made on CV1 cells in comparison to HeLa cells than wild-type virus, a slightly small-plaque phenotype on HeLa cells, a higher particle/ PFU ratio on HeLa cells than wild-type virus, and a fivefold-lower virus yield in single-cycle infections on either HeLa or CV1 cells. That the phenotypic defects of VP1-101 were caused by mutation of the viral protein and not the viral RNA alone was shown by the partial complementation of the VP1-101 phenotype by wild-type capsid proteins (Table 3) . Therefore, the small deletion in the amino terminus of VP1 is responsible for both the biochemical defect in RNA release and the phenotypic defects in virus growth. To rationalize the plaque reduction phenotype on CV1 cells, either an increased sensitivity to defects in RNA release for CV1 cells or the direct participation of a cellular component in viral RNA release must be invoked.
Deletion of amino acids 1 to 4 of VP1 of Mahoney serotype 1 poliovirus, the mutation borne by VP1-102, also caused a delay in RNA release mediated by either CV1 or HeLa cells.
An additional biochemical defect, in RNA packaging, was discovered for this mutant: the amount of encapsidation of viral RNA, as measured by the relative abundance of RNAcontaining and empty viral and subviral particles, was diminished in VP1-102 infections of both CV1 and HeLa cells. The VP1-102 mutation also caused the phenotype of the VP1-102 mutant virus: very small plaques on both CV1 and HeLa cells, a 50-fold decrease in virus titer in single-cycle infections of either cell line, a reduction in the relative numbers of plaques on CV1 cells, and a higher particle/PFU ratio than wild-type virus prepared under the same conditions. Some aspect of the mutant phenotype was caused by the defective VP1-102 protein alone, because VP1-102 virus displayed partial dominance during coinfection with wildtype virus (Table 4 ). The VP1-102 mutations is thus responsible both for biochemical defects in RNA release from the virion and RNA packaging and for the phenotypic defects discussed above.
These two different alleles of VP1 demonstrate, therefore, that RNA packaging into viral particles and RNA release from viral particles are related but separable genetic functions. Somehow, the amino terminus of VP1 is intimately involved in both these functions. Recent refinement of the three-dimensional structure of Mahoney serotype 1 poliovirus has revealed the locations of a few of the most aminoterminal residues of VP1 (14) . Figure 7 presents a view from the inside of the viral particle of the network formed by VP4 and the amino-terminal extensions of VP1, VP2, and VP3 (17) . An arrow denotes residue 20 of VP1; the more aminoterminal residues are not shown in this diagram, but density corresponding to several of them comprises a third betastrand, hydrogen bonded to VP4 near the fivefold symmetry axis (14) .
During the cell-mediated structural alteration of poliovirions that results in loss of elutable, infectious virus, VP4 is lost from the viral capsid (10) , and the resulting particles become more lipophilic (21) . The amino terminus of VP4 has been shown to be myristylated in intact virions (8) ; the presence of this hydrophobic moiety may facilitate the structural transition. Subsequent to structural alteration, the slightly hydrophobic amino termini of VP1 become more sensitive to proteolysis, a change thought to correspond to an extrusion of these portions of VP1 (14) . I have shown here that the cell-mediated structural changes leading to loss of viral infectivity are unaffected by small deletions in the amino terminus of VP1. Less is known about the subsequent change in the virion leading to RNA release; this process is critically affected, however, by the small deletions in the VP1-101 and VP1-102 mutants.
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If RNA encapsidation were the microscopic reverse of RNA release, it would be expected that mutants demonstrating slower release of RNA might display more rapid RNA packaging. While this may be the case for VP1-101, it certainly is not for VP1-102, which shows delayed kinetics for both processes (Fig. 5 and 6 ). That the two processes show some genetic and perhaps mechanistic features, however, was suggested by their simultaneous impairment in the VP1-102 mutant.
Several picornavirus mutants defective in various stages of entry into cells have been sequenced, and some have been characterized by reconstruction to substantiate that the detected lesion is responsible for the mutant phenotype. Targeted mutations were constructed in the proposed receptor-binding site of human rhinovirus type 14 (9) ; several of the resulting mutants were specifically defective in binding to susceptible cells, supporting the idea that the deep indentation or canyon encircling the five-fold symmetry axis of rhinovirus is the receptor-binding site (9, 33) . Replacement of six amino acids in VP1 of Mahoney serotype 1 poliovirions with amino acids from a similar position in Lansing serotype 2 poliovirions resulted in the simultaneous transfer of the Lansing phenotype of neurovirulence in mice (27) . This effect may have resulted from the acquisition by the hybrid virus of the ability to bind to mouse receptors (27) . The changed residues are located in a loop near the fivefold symmetry axis of the particles, neighboring but not constituting the proposed receptor-binding site (33) . The threedimensional structure of a human rhinovirus 14 variant that is resistant to inhibition by certain antiviral compounds has been determined, and a mutation has been found within the drug-binding site (2) . In the present work, two defined Mahoney serotype 1 poliovirus mutants have been described that carry mutations that specifically affect a later stage of virus entry into cells, the physical release of the viral RNA from the capsid. An unexpected connection between RNA release and RNA encapsidation was shown by the concomitant defects in both these processes in one of the mutants. The location of the responsible mutations in the amino terminus of VP1 suggests a direct role for these sequences in viral RNA manipulation during cell entry and virion morphogenesis of wild-type poliovirions. 
